Rahul Singhvi, Resilience CEO

A Bob Nelsen start­up turns to Har­vard to help sharp­en its tech, in­spir­ing first spin­out

One of Bob Nelsen’s lat­est projects is head­ed to Har­vard.

Re­silience, a com­pa­ny start­ed with the goal of es­tab­lish­ing it­self as a “one-stop-shop” for com­pa­nies look­ing to scale man­u­fac­tur­ing, in­clud­ing for hard-to-de­vel­op cell and gene ther­a­pies, is less than a year old. Fri­day, it an­nounced a five-year R&D deal with Har­vard Uni­ver­si­ty that in­cludes $30 mil­lion to de­vel­op bi­o­log­ics, in­clud­ing vac­cines, nu­cle­ic acids and cell and gene ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.